Advertisement
New Zealand markets closed
  • NZX 50

    11,796.21
    -39.83 (-0.34%)
     
  • NZD/USD

    0.5899
    -0.0007 (-0.12%)
     
  • NZD/EUR

    0.5521
    -0.0024 (-0.43%)
     
  • ALL ORDS

    7,817.40
    -81.50 (-1.03%)
     
  • ASX 200

    7,567.30
    -74.80 (-0.98%)
     
  • OIL

    82.50
    -0.23 (-0.28%)
     
  • GOLD

    2,393.60
    -4.40 (-0.18%)
     
  • NASDAQ

    17,322.96
    -71.35 (-0.41%)
     
  • FTSE

    7,835.77
    -41.28 (-0.52%)
     
  • Dow Jones

    37,808.39
    +33.01 (+0.09%)
     
  • DAX

    17,728.71
    -108.69 (-0.61%)
     
  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     
  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     
  • NZD/JPY

    91.1320
    -0.1220 (-0.13%)
     

Intra-Cellular Therapies to Present at the Goldman Sachs 44th Annual Global Healthcare Conference

Intra-Cellular Therapies Inc.
Intra-Cellular Therapies Inc.

NEW YORK, June 05, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will present at the Goldman Sachs 44th Annual Global Healthcare Conference on Monday, June 12, 2023 at 2:00 p.m. PT.

The live and archived webcast can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.

About Intra-Cellular Therapies

Intra-Cellular Therapies is a biopharmaceutical company founded on Nobel prize-winning research that allows us to understand how therapies affect the inner-workings of cells in the body. The company leverages this intracellular approach to develop innovative treatments for people living with complex psychiatric and neurologic diseases. For more information, please visit www.intracellulartherapies.com.

ADVERTISEMENT

Contact:

Intra-Cellular Therapies, Inc.
Juan Sanchez, M.D.
Vice President, Corporate Communications and Investor Relations
646-440-9333

Burns McClellan, Inc.
Cameron Radinovic
cradinovic@burnsmc.com
212-213-0006